JP2025504027A - セラグノスティクス葉酸コンジュゲート - Google Patents

セラグノスティクス葉酸コンジュゲート Download PDF

Info

Publication number
JP2025504027A
JP2025504027A JP2024544930A JP2024544930A JP2025504027A JP 2025504027 A JP2025504027 A JP 2025504027A JP 2024544930 A JP2024544930 A JP 2024544930A JP 2024544930 A JP2024544930 A JP 2024544930A JP 2025504027 A JP2025504027 A JP 2025504027A
Authority
JP
Japan
Prior art keywords
compound
compound according
radiometal
effective amount
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504027A5 (enExample
Inventor
ヴィオーラ グレーン、
マリー－ルイーゼ レンツ、
ルドルフ モーザー、
ロジャー シブリ、
クリスティーナ マグダレナ ミュラー、
ルイーザ マリア デベルレ、
アンナ エリーザベト ベッカー、
ザーラ ドーリナ ブシュリンゲル、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2025504027A publication Critical patent/JP2025504027A/ja
Publication of JP2025504027A5 publication Critical patent/JP2025504027A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024544930A 2022-02-01 2023-01-30 セラグノスティクス葉酸コンジュゲート Pending JP2025504027A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154652 2022-02-01
EP22154652.6 2022-02-01
PCT/EP2023/052117 WO2023148116A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (2)

Publication Number Publication Date
JP2025504027A true JP2025504027A (ja) 2025-02-06
JP2025504027A5 JP2025504027A5 (enExample) 2026-02-12

Family

ID=80118841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544930A Pending JP2025504027A (ja) 2022-02-01 2023-01-30 セラグノスティクス葉酸コンジュゲート

Country Status (9)

Country Link
US (1) US20250127938A1 (enExample)
EP (1) EP4472677A1 (enExample)
JP (1) JP2025504027A (enExample)
KR (1) KR20240146013A (enExample)
CN (1) CN118647412A (enExample)
AU (1) AU2023216406A1 (enExample)
CA (1) CA3243584A1 (enExample)
IL (1) IL314508A (enExample)
WO (1) WO2023148116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025227100A2 (en) * 2024-04-26 2025-10-30 Purdue Research Foundation Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases

Also Published As

Publication number Publication date
CN118647412A (zh) 2024-09-13
WO2023148116A1 (en) 2023-08-10
CA3243584A1 (en) 2023-08-10
US20250127938A1 (en) 2025-04-24
AU2023216406A1 (en) 2024-09-19
KR20240146013A (ko) 2024-10-07
EP4472677A1 (en) 2024-12-11
IL314508A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
EP2948186A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
JP2025504028A (ja) セラグノスティクス葉酸コンジュゲート
JP2025504027A (ja) セラグノスティクス葉酸コンジュゲート
HK40109744A (zh) 治疗诊断学叶酸酯缀合物
HK40110380A (zh) 治疗诊断学叶酸酯缀合物
WO2022233768A1 (en) Precursor and radiotracer for neuroendocrine theranostics
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
HK40054611A (en) Novel tumor antigen binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203